Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.99 -0.45 (-0.93%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

30 31 32 33 34 35 36 37 Next >

IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize ↗

June 01, 2022

One analyst expects multiple new drug launches between 2024-26.

Via Investor's Business Daily

Cathie Wood Provides Lesson of the Day: Don't Invest in Fairytale Stocks ↗

May 20, 2022

Tesla is no longer the No.1 holding of Cathie Wood's ARK. Let's see what's inside.

Via Talk Markets

Why Orphan Drug Designation Offers Several Benefits

May 18, 2022

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here we...

Via FinancialNewsMedia

Analyst Ratings for CRISPR Therapeutics ↗

May 17, 2022

Over the past 3 months, 11 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

How to Buy Stocks in a Recession ↗

May 16, 2022

The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward.

Via InvestorPlace

5 Cathie Wood Stocks to Buy Now ↗

May 16, 2022

ARK Invest funds led by Cathie Wood seek long-term capital growth and focus mainly on disruptive innovation. Here's a look a five related stocks to consider.

Via InvestorPlace

Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis ↗

May 12, 2022

Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.

Via Investor's Business Daily

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data ↗

May 10, 2022

Via Benzinga

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much ↗

May 02, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About CRISPR Therapeutics ↗

April 28, 2022

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

Via Benzinga

3 Cathie Wood Stocks to Count on in Q2 ↗

April 26, 2022

These Cathie Wood Stocks have their risks but offer a massive upside potential ahead, especially if you can handle the volatility.

Via InvestorPlace

7 Potential Biotech Stocks Buyout Targets in 2022 ↗

April 21, 2022

Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.

Via InvestorPlace

$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much ↗

April 20, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a...

Via Benzinga

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

April 01, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a...

Via Benzinga

3 Best Stocks to Trade Right Now ↗

March 24, 2022

Get past the persistently bearish headlines, and you'll find stocks to trade long in emerging bull markets that could be lucrative.

Via InvestorPlace

Fed Rate Hike Rallies Stocks ↗

March 17, 2022

The Federal Reserve led by Jerome Powell hiked interest rates for the first time in three years causing stocks to rally.

Via Talk Markets

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗

March 16, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.95% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have...

Via Benzinga

3 Ark Invest Most-Shorted Stocks to Buy ↗

March 11, 2022

These most-shorted stocks have investors seeing red, but there is a silver lining that's playing out on the price chart for today's buyers.

Via InvestorPlace

7 Cathie Wood Stocks That Are Worth Buying in March ↗

March 10, 2022

Many Cathie Wood stocks have suffered losses over the past year, but these companies will likely see strong gains in the coming quarters.

Via InvestorPlace

3 Cathie Wood Stocks to Buy ↗

March 09, 2022

Don't buy Cathie Wood stocks because the market was singing on Wednesday, purchase them because of a much bigger and bullish picture.

Via InvestorPlace

Tough Slogging Ahead for Investors, Diversification is Important ↗

March 07, 2022

Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.

Via Talk Markets

Intellia Therapeutics Crashes As Patent Decision Clouds CRISPR Gene-Editing Test ↗

February 28, 2022

Intellia Therapeutics said its gene-editing drug lowered levels of a troublesome protein.

Via Investor's Business Daily

Peloton Isn’t the ONLY Takeover Target. What Companies Could Be Bought Out in 2022? ↗

February 23, 2022

Savvy investors can generate lucrative returns by investing in companies that look like a number of prime takeover targets.

Via InvestorPlace

Why Jim Cramer Believes Sirius XM Is Inexpensive ↗

February 23, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ:

Via Benzinga

What Are Whales Doing With CRISPR Therapeutics ↗

February 22, 2022

A whale with a lot of money to spend has taken a noticeably bullish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 15 strange trades.

Via Benzinga

CRISPR Therapeutics's Return On Capital Employed Insights ↗

February 16, 2022

Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter.

Via Benzinga

Week In Review: Xbiome Acquires Diabetic Foot Ulcer Therapy In $139 Million Deal ↗

January 29, 2022

Xbiome, a Shenzhen AI-based microbiome drug development company, in-licensed China rights to an inflammatory disease therapy developed by Aurealis, a Swiss synthetic biology company, in a deal worth up...

Via Talk Markets

Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years ↗

January 25, 2022

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis. Buying $1,000 In CRSP: 5 years ago, an investor could have...

Via Benzinga

Stock Market Rebound Fizzles Amid Hawkish Fed; Taiwan Semiconductor Breaks Out, JPMorgan Tumbles: Weekly Review ↗

January 14, 2022

A rebound from Monday's lows faded, with the key indexes all down for the week.

Via Investor's Business Daily

< Previous 1 2

...

30 31 32 33 34 35 36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.